258 related articles for article (PubMed ID: 34797911)
1. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
2. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Romee R; Cooley S; Berrien-Elliott MM; Westervelt P; Verneris MR; Wagner JE; Weisdorf DJ; Blazar BR; Ustun C; DeFor TE; Vivek S; Peck L; DiPersio JF; Cashen AF; Kyllo R; Musiek A; Schaffer A; Anadkat MJ; Rosman I; Miller D; Egan JO; Jeng EK; Rock A; Wong HC; Fehniger TA; Miller JS
Blood; 2018 Jun; 131(23):2515-2527. PubMed ID: 29463563
[TBL] [Abstract][Full Text] [Related]
3. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
[TBL] [Abstract][Full Text] [Related]
4. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
7. Anti-Relapse effects of donor natural killer cells and IL-2 gene modification on allogeneic hematopoietic stem cell transplantation in acute leukemia.
Xue Z; Gao Y; Wu X
Cancer Biomark; 2020; 29(2):207-219. PubMed ID: 32568180
[TBL] [Abstract][Full Text] [Related]
8. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
9. IL-15 Upregulates Telomerase Expression and Potently Increases Proliferative Capacity of NK, NKT-Like, and CD8 T Cells.
Watkinson F; Nayar SK; Rani A; Sakellariou CA; Elhage O; Papaevangelou E; Dasgupta P; Galustian C
Front Immunol; 2020; 11():594620. PubMed ID: 33537030
[TBL] [Abstract][Full Text] [Related]
10. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
11. IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
Song Y; Hu B; Liu Y; Jin Z; Zhang Y; Lin D; Zhu Y; Lei L; Gong H; Mei Y; Teo HY; Wu D; Liu H
Eur J Immunol; 2018 Apr; 48(4):670-682. PubMed ID: 29282719
[TBL] [Abstract][Full Text] [Related]
12. Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.
Bachanova V; Sarhan D; DeFor TE; Cooley S; Panoskaltsis-Mortari A; Blazar BR; Curtsinger JM; Burns L; Weisdorf DJ; Miller JS
Cancer Immunol Immunother; 2018 Mar; 67(3):483-494. PubMed ID: 29218366
[TBL] [Abstract][Full Text] [Related]
13. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
14. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT.
Sauter CT; Bailey CP; Panis MM; Biswas CS; Budak-Alpdogan T; Durham A; Flomenberg N; Alpdogan O
Bone Marrow Transplant; 2013 Sep; 48(9):1237-42. PubMed ID: 23624821
[TBL] [Abstract][Full Text] [Related]
16. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
18. Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation.
Nguyen S; Béziat V; Norol F; Uzunov M; Trebeden-Negre H; Azar N; Boudifa A; Bories D; Debré P; Vernant JP; Vieillard V; Dhédin N
Transfusion; 2011 Aug; 51(8):1769-78. PubMed ID: 21332732
[TBL] [Abstract][Full Text] [Related]
19. Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy.
Maia A; Tarannum M; Lérias JR; Piccinelli S; Borrego LM; Maeurer M; Romee R; Castillo-Martin M
Cells; 2024 Mar; 13(5):. PubMed ID: 38474415
[TBL] [Abstract][Full Text] [Related]
20. Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
Cooley S; Parham P; Miller JS
Blood; 2018 Mar; 131(10):1053-1062. PubMed ID: 29358179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
